APA

Al Askar A. S., Shaheen N. A., Al Zahrani M., Al Otaibi M. G., Al Qahtani B. S., Ahmed F., Al Zughaibi M., Kamran I., Mendoza M. A. & Khan A. (20180419). Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience. : International journal of hematology.

Chicago

Al Askar Ahmed S, Shaheen Naila A, Al Zahrani Mohsen, Al Otaibi Mohammed G, Al Qahtani Bader S, Ahmed Faris, Al Zughaibi Mohand, Kamran Ismat, Mendoza May Anne and Khan Altaf. 20180419. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience. : International journal of hematology.

Harvard

Al Askar A. S., Shaheen N. A., Al Zahrani M., Al Otaibi M. G., Al Qahtani B. S., Ahmed F., Al Zughaibi M., Kamran I., Mendoza M. A. and Khan A. (20180419). Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience. : International journal of hematology.

MLA

Al Askar Ahmed S, Shaheen Naila A, Al Zahrani Mohsen, Al Otaibi Mohammed G, Al Qahtani Bader S, Ahmed Faris, Al Zughaibi Mohand, Kamran Ismat, Mendoza May Anne and Khan Altaf. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience. : International journal of hematology. 20180419.